Hyatt Hotels Corporation vs Eli Lilly And Co — how do they compare? Hyatt Hotels Corporation trades at $161.94 (market cap $15.02B), while Eli Lilly And Co trades at $1,179.27 (market cap $1.04T). The key difference: Eli Lilly And Co is far larger — about 69.2× Hyatt Hotels Corporation's market cap, and Eli Lilly And Co pays the higher dividend (0.59%). Which is the better fit depends on your goals — on Pluang, investors hold Hyatt Hotels Corporation for 148 Days and Eli Lilly And Co for 93 Days on average.
| H | LLY | |
|---|---|---|
Market Cap | $15.02B | $1.04T |
Volume | 842,340 | 3,064,878 |
Sector | Consumer Cyclical | Health |
52-Week High | $202.09 | $1.28K |
52-Week Low | $135.42 | $799.57 |
Typical Hold Time | 148 Days | 93 Days |
Enterprise Value | $18.93B | $1.09T |
Dividend Yield | 0.38% | 0.59% |
Signals from Pluang's Aura AI — not financial advice
Hyatt Hotels Corporation (H) trades at $159.43, up 1.46% today, with a neutral technical stance and mixed fundamentals. The stock has beaten earnings estimates for three consecutive quarters, but profitability metrics remain thin with a net margin of 1.1% and elevated P/E of 196.83. Recent news highlights brand expansion and a strategic loyalty collaboration with Delta Air Lines, signaling growth initiatives amid a challenging profit environment.
The outlook balances growth potential from fee expansion and new partnerships against high valuation and earnings volatility. Risks include project delays, debt levels, and regional economic sensitivity. Analyst consensus is a Moderate Buy with a $197.77 price target, suggesting 24% upside, but investors face headwinds from margin pressure and competitive dynamics in the hospitality sector.
Eli Lilly (LLY) trades at $1,169.93, down 1.58% on the day, but maintains strong bullish momentum with consistent earnings beats and robust revenue growth. The company demonstrates exceptional profitability with 83.4% gross margins and 33.53% net income margins, supported by dominant positioning in weight-loss and diabetes treatments. Recent clinical trial successes for next-generation drugs and expanded FDA approvals reinforce growth prospects.
LLY presents compelling growth potential with analyst consensus target of $1,350 representing 15% upside, though elevated valuations (P/E 39.26) and increasing competition in obesity drugs pose risks. Strong institutional support (73% buy ratings) and positive pipeline developments support continued momentum, but investors should monitor execution risks and market saturation concerns.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
Latest headlines on both assets
Hyatt is an operator of 1,162 owned (5% of total rooms) and managed and franchise (95%) properties across roughly 20 upscale luxury brands, which includes vacation brands (Apple Leisure Group, Hyatt Ziva and Hyatt Zilara), the recently launched full-service lifestyle brand Hyatt Centric, the soft lifestyle brand Unbound, and the wellness brand Miraval. Hyatt acquired Two Roads in November 2018 and Apple Leisure Group in 2021. The regional exposure as a percentage of total rooms is 66% Americas, 18% Asia-Pacific, and 16% rest of world.
Read more on H →Eli Lilly is a drug firm with a focus on neuroscience, endocrinology, cancer, and immunology. Lilly's key products include Verzenio for cancer
Read more on LLY →